A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Tensha Therapeutics
Information provided by (Responsible Party):
Tensha Therapeutics
ClinicalTrials.gov Identifier:
First received: November 5, 2013
Last updated: March 4, 2015
Last verified: March 2015

November 5, 2013
March 4, 2015
October 2013
March 2016   (final data collection date for primary outcome measure)
  • Maximum tolerated dose and dose-limiting toxicities as determined in Part A. [ Time Frame: End of Cycle 1 (Day 28) ] [ Designated as safety issue: Yes ]
    Toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v 4.03).
  • Safety parameters [ Time Frame: Parts A and B: at a minimum Days 1, 8, 15, 22 of each treatment cycle. ] [ Designated as safety issue: Yes ]
    Physical examination, clinical safety laboratory tests, assessment of adverse events, Eastern Cooperative Oncology Group Performance Status (ECOG PS), chest X-ray, Electrocardiogram (ECG), vital signs, and concomitant medication review.
Same as current
Complete list of historical versions of study NCT01987362 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: Cycle 1 Day 1, Day 8, Day 15, Cycle 2 Day 1, Day 15, Day 22. ] [ Designated as safety issue: No ]
    Plasma levels of TEN-010 will be measured during the treatment and follow-up periods. Pharmacokinetic variables to be calculated are AUC, Cmax, and Tmax.
  • Efficacy [ Time Frame: At baseline, at the end of Cycle 2 (2 months), and every 2 cycles (2 months) thereafter until disease progression or death. ] [ Designated as safety issue: No ]
    Response to treatment evaluated using the Response Evaluation Criteria in Solid Tumors guidelines (RECIST 1.1).
Same as current
Not Provided
Not Provided
A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously
A Two Part, Phase 1, Multicenter, Open-label Study of TEN-010 Given Subcutaneously. Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies.
TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, pharmacokinetics and anti-tumor activity of TEN-010 in patients who are refractory or intolerant to standard/approved therapies. This first-in-human study of TEN-010 will be conducted in two parts: dose escalation and dose expansion. For dose escalation (Part A), a standard "3+3" design will be used in which successive cohorts of three or more patients with advanced solid tumor malignancies will be treated at escalating doses until a maximum tolerated dose (MTD) is identified. For the dose expansion part of the study (Part B), a subset of patients with advanced solid malignancies will be treated with TEN-010 at the MTD (or the highest dose tested if the MTD is not defined) to further characterize safety and biological effect. In addition, up to 10 patients with nuclear protein in testis (NUT) midline carcinoma (NMC) will be permitted to enroll in a substudy of the protocol.
This is a Phase 1 non-randomized, dose-escalating, open label, multi-center study to be conducted in two parts (Part A and Part B). A maximum of 56 patients aged 18 years or older with histologically confirmed advanced solid tumors with progressive disease requiring therapy will be enrolled in the study. It is expected that approximately 36 patients will be enrolled in 6 cohorts of up to 6 patients per cohort in Part A of the study and 20 additional patients will be enrolled in Part B of the study. Up to 10 patients with NMC may be enrolled as part of a substudy within the protocol.
Phase 1
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Solid Tumors
Drug: TEN-010
Safety, tolerability and pharmacokinetics of TEN-010 in Patients with Advanced Solid Malignancies.
Experimental: Treatment
Intervention: Drug: TEN-010
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2016
March 2016   (final data collection date for primary outcome measure)



  • Patients with solid tumors must have one or more metastatic tumors evaluable or measurable on radiographic imaging
  • Ambulatory patients >= 18 years of age
  • ECOG performance status of 0 or 1 (or 2 upon approval by the medical monitor)
  • Life expectancy of >= 3 months
  • Disease-free of active second/secondary or prior malignancies >= 2 years with the exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in-situ" of the cervix or breast
  • Adequate hematological, renal, hepatic and coagulation laboratory test results.
  • Women of child bearing potential and men must agree to use adequate contraception during the study and for 4 months after the last dose of study drug.
  • Available for the duration of the study and willing to follow study procedures
  • Provide written informed consent

Advanced Solid Malignancies

  • Patients with previously treated, histologically confirmed advanced solid malignancy with progressive disease requiring therapy
  • Patients must be refractory or intolerant to standard therapy

NUT-midline carcinoma

  • Patients with histologically confirmed newly diagnosed or relapsed/refractory NUT-midline carcinoma (NMC) with progressive disease requiring therapy
  • Diagnosis of one of the following is required:

    1. NUT Midline Carcinoma based on ectopic expression of NUT protein as determined by Immunohistochemistry (IHC) and/or;
    2. Detection of NUT gene translocation as determined by Fluorescence In-Situ Hybridization (FISH).


  • Patients with hematologic malignancies
  • New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia
  • Have QTcF > 470 msec (female) or > 450 (male), or history of congenital long QT syndrome
  • Active, uncontrolled bacterial, viral, or fungal infections
  • Known clinically important respiratory impairment
  • Positive for HIV, hepatitis B surface antigen, or hepatitis C antibodies
  • History of major organ transplant
  • History of an autologous or allogeneic bone marrow transplant
  • Symptomatic central nervous system malignancy or metastasis
  • Pregnant or nursing
  • Treatment with surgery or chemotherapy within 28 days prior to study entry
  • Prior treatment with small molecule (BET) family inhibitor
  • Radiation for symptomatic lesions within 14 days of study enrollment
  • Other exclusions apply
18 Years and older   (Adult, Senior)
United States
Not Provided
Not Provided
Tensha Therapeutics
Tensha Therapeutics
Not Provided
Study Director: Steve Landau, MD Tensha Therapeutics
Tensha Therapeutics
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP